Table 1.

Clinical characteristics of the patients included in the study


Patient no.

CD4 cell count/mm3

Treatment
1   887   AZT-3TC-EFV  
2   566   ddl-3TC-EFV  
3   625   AZT-3TC-EFV  
4   593   D4T-3TC-NFV  
5   974   D4T-3TC-NFV  
6   626   AZT-3TC-NFV  
7   1285   D4T-3TC-NVP  
8   555   ddl-TDF-LPV  
9   607   AZT-3TC-EFV  
10   638   AZT-3TC-NFV  
11   518   AZT-3TC-ABC-LPV  
12   505   3TC-NVP-TDF  
13   518   AZT-3TC-ABC-LPV  
14   664   AZT-DDI-NVP  
15
 
555
 
AZT-3TC-EFV
 

Patient no.

CD4 cell count/mm3

Treatment
1   887   AZT-3TC-EFV  
2   566   ddl-3TC-EFV  
3   625   AZT-3TC-EFV  
4   593   D4T-3TC-NFV  
5   974   D4T-3TC-NFV  
6   626   AZT-3TC-NFV  
7   1285   D4T-3TC-NVP  
8   555   ddl-TDF-LPV  
9   607   AZT-3TC-EFV  
10   638   AZT-3TC-NFV  
11   518   AZT-3TC-ABC-LPV  
12   505   3TC-NVP-TDF  
13   518   AZT-3TC-ABC-LPV  
14   664   AZT-DDI-NVP  
15
 
555
 
AZT-3TC-EFV
 

The viral load was less than 50 copies/mL for patients 1 through 15. All patients have received HAART for at least 1 year. AZT indicates zidovudine; 3TC, lamivudine; EFV, efavirenz; ddl, didanosine; D4T, stavudine; NFV, nelfinavir; NVP, nevirapine; TDF, tenofovir; LPV, lopinavir; and ABC, abacavir.

or Create an Account

Close Modal
Close Modal